INTS
Intensity Therapeutics, Inc.·Healthcare
4.51
3.729%(−0.17)
Market OpenLast Updated: — ET
52W L: $4.4552W H: $43.50
INTS NEWS
zacks.com
6h ago
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
prnewswire.com
May 14
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Company receives the Cancer Treatment Technology Innovator of the Year award SHELTON, Conn., May 14, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Cancer Treatment Technology Innovator of the Year 2026 – USA award recipient.
prnewswire.com
May 7
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Cash and cash equivalents of $10.2 million as of March 31, 2026 Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below) Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026 Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026 SHELTON, Conn., May 7, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces first quarter 2026 financial results and provides a corporate update.
zacks.com
May 1
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
zacks.com
Apr 16
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
prnewswire.com
Apr 15
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Company receives the Platinum Award for Innovator in Biotech Solutions Category SHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and lead drug candidate INT230-6.
